Third quarter 2024 U.S. BRIUMVI net revenue of $83.3 million Raises full year 2024 U.S. BRIUMVI net revenue target to $300 - $305 million Conference call to be held today, November 4, 2024, at 8:30 AM ...
Positive Interim Analysis of Phase 3 ENSURE Program, Unblinded Independent Data Monitoring Committee Confirmed that Predetermined Futility Criteria Have Not Been Met and Recommended Trials Should ...
2d
NEW YORK, November 7, 2024 – Immunic, Inc. (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and ...
Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with ...
More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com. Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central ...
More information about the BRIUMVI Patient Support program can be accessed at . Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS ...
Yes. Thank you, Jason. In October, we announced a positive outcome of the interim analysis of our Phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis or RMS. An Independent ...
Novartis has secured backing from NICE for its relapsing multiple sclerosis (RMS) therapy Kesimpta in the UK, just two weeks after the drug was approved by the national drugs regulator.
TG Therapeutics (NASDAQ:TGTX – Free Report) had its target price increased by HC Wainwright from $49.00 to $55.00 in a report ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback